EP3294345
TPP1-samsetningar og aðferðir til meðhöndlunar á CLN2 sjúkdómi
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
5.5.2016EP published:
18.10.2023EP application number:
16793229.2
EP translation filed:
15.1.2024Grant published:
15.2.2024EPO information:
European Patent Register
Max expiry date:
4.5.2036Expiry date:
4.5.2026Next due date:
31.5.2026
Title in English:
TPP1 FORMULATIONS AND METHODS FOR TREATING CLN2 DISEASELanguage of the patent:
English
Timeline
Today
5.5.2016EP application
18.10.2023EP Publication
15.1.2024Translation submitted
15.2.2024Registration published
4.5.2026Expires
Owner
Name:
BioMarin Pharmaceutical Inc.Address:
105 Digital Drive, Novato, CA 94949, US
Inventor
Name:
LESTER, Thomas, W.Address:
Castro Valley, CA 94546-3552, US
Name:
MOSHASHAEE, SaeedAddress:
San Rafael, CA 94903, US
Name:
OKHAMAFE, Augustus, O.Address:
Concord, CA 94521, US
Name:
O'NEILL, Charles, A.Address:
Vineburg, CA 95487, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201562158789 PDate:
8.5.2015Country:
US
Number:
201662300171 PDate:
26.2.2016Country:
US
Classification
Categories:
A61K 9/08, A61K 49/14, A61K 48/00, A61P 25/28
Annual fees
Number
Paid
Expires
Payer
Number: 9
Paid: 19.4.2024
Expires: 4.5.2025
Payer: Árnason Faktor ehf.
Number: 10
Paid: 5.5.2025
Expires: 4.5.2026
Payer: Árnason Faktor ehf.